LEXINGTON, Ky., May 14, 2025 /PRNewswire/ -- Ramaco Resources, Inc. (NASDAQ: METC, METCB) Ramaco is proud to announce that Aurelia Skipwith Giacometto, a valued member of the Ramaco Resources, Inc., Board of Directors, has joined Earth & Water Law, LLC (E&W Law) as a partner. Aurelia has over 20 years of experience in agriculture, wildlife conservation, and energy development. Most recently, she served as the 14th Secretary of the Louisiana Department of Environmental Quality (LDEQ). In 2019, prior to her p ...

PALO ALTO, Calif., May 14, 2025 /PRNewswire/ -- Kodiak Sciences Inc. (Nasdaq: KOD), today reported recent business highlights and financial results for the first quarter ended March 31, 2025."In the first quarter of 2025, we maintained a strong focus on execution. We look forward to sharing our progress at an Investor R&D Update scheduled for July 16, 2025 at 1:00pm Eastern Time. We aim to demonstrate that our vision for Kodiak 2.0 as a precommercial stage retina focused biotech company with a maturing port ...

FAIRBANKS, Alaska, May 14, 2025 /PRNewswire/ - Contango ORE, Inc. ("Contango" or the "Company") (NYSE American: CTGO) announced today that it filed with the Securities and Exchange Commission its Form 10-Q for the quarter ended March 31, 2025 ("Q1-2025") compared with the quarter ended March 31, 2024 ("Q1-2024").The Company reported total income for operations of $19.3 M in Q1-2025 compared to a loss of $2.9 M for Q1-2024. For Q1-2025, the Company reported a net loss of $22.3 M, including a non-cash expense ...

Core Insights - Oruka Therapeutics is advancing its clinical programs ORKA-001 and ORKA-002, which target chronic skin diseases like plaque psoriasis, with the potential to set a new treatment standard [2][12] Pipeline Developments - ORKA-001, targeting IL-23p19, has completed Phase 1 trial dosing, with data expected in Q3 2025. Phase 2a initiation is anticipated in 2H 2025, with efficacy readout expected in 2H 2026 [1][5] - ORKA-002, targeting IL-17A/F, has accelerated its Phase 1 initiation to Q2 2025, with initial pharmacokinetic (PK) data expected by the end of 2025 [1][5] - The Phase 2a study for ORKA-001 will enroll approximately 80 patients and aims for a primary endpoint of PASI 100 at week 16, which is more ambitious than previous studies [5] Financial Position - As of March 31, 2025, Oruka has a strong cash position of $373 million, providing a runway through 2027 [1][7] - Research and Development (R&D) expenses for Q1 2025 totaled $19.9 million, reflecting increased investment in clinical development [8] - General and Administrative (G&A) expenses for Q1 2025 were $5.2 million, driven by employee compensation and operational growth [9] Clinical Data and Efficacy - Interim data from the ORKA-001 Phase 1 trial is expected in Q3 2025, with a focus on safety, tolerability, and pharmacokinetics [5] - ORKA-002 has shown a half-life in non-human primates of over 30 days, supporting a dosing interval of two to three times per year [5] Market Potential - The company aims to achieve high rates of complete disease clearance for patients with chronic skin diseases, with dosing as infrequently as once or twice a year [12]

Group 1 - Kronos Worldwide, Inc. declared a regular quarterly dividend of five cents ($0.05) per share on its common stock, payable on June 18, 2025, to stockholders of record at the close of business on June 9, 2025 [1] - At the 2025 annual stockholder meeting, stockholders elected several directors for a one-year term [2] - A nonbinding advisory resolution was adopted to approve the compensation of named executive officers as disclosed in the proxy statement for the 2025 annual stockholder meeting [2] Group 2 - Kronos Worldwide, Inc. is identified as a major international producer of titanium dioxide products [1]

Group 1 - O-I Glass, Inc. announced the retirement of Alan J. Murray from its Board of Directors after many years of service [1][2] - At the Annual Meeting, 11 director nominees were elected for one-year terms, including new members Eugenio Garza y Garza and Iain J. Mackay [1] - The company expressed gratitude for Mr. Murray's service and welcomed the new board members, highlighting their extensive global business and financial reporting expertise [2] Group 2 - O-I Glass is a leading producer of glass bottles and jars, emphasizing the sustainability and recyclability of glass as a packaging material [3] - The company achieved net sales of $6.5 billion in 2024 and operates approximately 69 plants in 19 countries with a diverse team of around 21,000 employees [3]

Financial Performance - Revenues for Q1 2025 were $80.1 million, a decrease from $111.1 million in Q1 2024 [6] - Profit for Q1 2025 was $12.6 million, down from $41.6 million in Q1 2024 [6] - Earnings per share for Q1 2025 were $0.39, compared to $1.29 in Q1 2024 [6] - Cash (including restricted cash) as of March 31, 2025, was $43.0 million, down from $54.3 million as of December 31, 2024 [6] Operational Metrics - Time charter equivalent (TCE) revenue for Q1 2025 was $48.6 million [6] - EBITDA and Adjusted EBITDA for Q1 2025 were $33.8 million and $32.5 million, respectively [6] - Fleetwide daily TCE rate was $38,500 per operating day in Q1 2025, with VLCC and Suezmax TCE rates at $38,000 and $39,200 per operating day, respectively [6] - Daily vessel operating expenses were $9,233 per calendar day in Q1 2025 [6] Dividend Declaration - The board of directors declared a dividend of $0.32 per common share, payable on June 12, 2025, to shareholders of record as of June 3, 2025 [4] - Common shares will be traded ex-dividend on the NYSE from June 3, 2025, and on the Oslo Stock Exchange from June 2, 2025 [4] Market Development - As of Q2 2025 to date, 72% of available VLCC spot days have been booked at an average TCE rate of $46,700 per day, and 64% of available Suezmax spot days have been booked at an average TCE rate of $50,600 per day [6]

Core Viewpoint - Edesa Biotech, Inc. is advancing its clinical-stage biopharmaceutical development, particularly focusing on its vitiligo drug candidate EB06, while reporting financial results that reflect a strategic pivot in operational activities towards this program [1][4]. Financial Overview - For the three months ended March 31, 2025, total operating expenses decreased by $0.6 million to $1.6 million compared to $2.2 million for the same period in 2024 [7] - The company reported a net loss of $1.6 million, or $0.30 per common share, for the quarter, an improvement from a net loss of $1.9 million, or $0.58 per common share, for the same quarter last year [8] - For the six months ended March 31, 2025, total operating expenses decreased by $0.6 million to $3.5 million compared to $4.1 million for the same period in 2024 [9] - The net loss for the six months was $3.2 million, or $0.74 per common share, compared to a net loss of $3.5 million, or $1.12 per common share, for the same period last year [11] Business Development - The company completed a $15 million equity financing to support the development of EB06, an anti-CXCL10 monoclonal antibody for vitiligo [2] - Edesa has initiated outreach to potential investigators and manufacturing activities to support U.S. regulatory approval for a Phase 2 study in moderate-to-severe nonsegmental vitiligo patients [2][6] - The planned Phase 2 study for EB06 is already approved in Canada, with drug manufacturing data expected to be submitted to the FDA in the second half of 2025 [6] Research and Development - Research and development expenses decreased by $0.7 million to $0.5 million for the three months ended March 31, 2025, primarily due to decreased external research expenses related to the investigational drug paridiprubart [9][16] - General and administrative expenses increased by $0.2 million to $1.2 million for the three months ended March 31, 2025, mainly due to increased salaries and related costs [9] Cash Position - As of March 31, 2025, Edesa had cash and cash equivalents of $13.9 million and working capital of $13.5 million [12]

Core Insights - Navitas Semiconductor has appointed Cristiano Amoruso to its board of directors, effective immediately, which is seen as a strategic move to enhance corporate governance and accelerate profitability [1][3] - Amoruso has a strong background in the technology and renewable energy sectors, having previously served as CEO of Suniva, Inc. and as a partner at Lion Point Capital, L.P. [2] - The company aims to leverage Amoruso's experience to capture significant market opportunities in the gallium nitride (GaN) and silicon carbide (SiC) sectors, particularly in power-intensive applications [3] Company Overview - Navitas Semiconductor is a pure-play, next-generation power semiconductor company, founded in 2014, specializing in GaN and SiC technologies [6] - The company offers GaNFast™ power ICs and GeneSiC™ power devices, focusing on markets such as data centers, electric vehicles, solar energy, and energy storage [6] - Navitas holds over 300 patents and was the first semiconductor company to achieve CarbonNeutral® certification [6]

Key Highlights - Battalion Oil Corporation has continued its drilling operations, completing four wells in the Monument Draw area and drilling ahead of schedule on two additional wells in West Quito [2] - The company reported average daily net production of 11,900 Boe/d (53% oil) and total operating revenue of $47.5 million for Q1 2025, compared to 12,989 Boe/d (48% oil) and $49.9 million in Q1 2024 [4] - The acid gas injection facility treated approximately 18 MMcf/d on average during Q1 2025, with subsequent increases in daily rates to over 30 MMcf/d [3] Management Comments - The company is in the final stages of drilling operations on the last well of its six-well activity plan for 2025, with capital expenditures on the first well in West Quito approximately $1.0 million under AFE [2] - Recently completed wells in the Monument Draw field are expected to deliver over 1,000,000 barrels of oil ultimate recovery each [2] Results of Operations - Battalion reported a net loss available to common stockholders of $5.8 million, or a net loss of $0.35 per share for Q1 2025, compared to a net loss of $36.8 million, or $2.24 per share in Q1 2024 [6][12] - Adjusted EBITDA for Q1 2025 was $15.1 million, an increase from $9.4 million in Q1 2024 [6] Financial Performance - Lease operating and workover expenses increased to $11.01 per Boe in Q1 2025 from $10.55 per Boe in Q1 2024, primarily due to inflationary market increases [5] - General and administrative expenses rose to $4.12 per Boe in Q1 2025 from $3.44 per Boe in Q1 2024, driven by higher payroll and benefits costs [5] Liquidity and Balance Sheet - As of March 31, 2025, the company had $225.0 million in term loan indebtedness and total liquidity of $73.6 million [9] - Current assets increased to $111.4 million as of March 31, 2025, compared to $54.1 million a year earlier [14]